secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2023-10-20T23:59:59+00:00
Accession:  0001193125-23-259961
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst Pharmaceuticals appoints Richard J. Daly as CEO, effective Jan 1, 2024
-------------------------------------------------------------------------------

- Patrick J. McEnany retires as CEO effective Dec 31, 2023, remains Chairman of the Board.
- Richard J. Daly, Board member since 2015, named CEO; previously President at CARsgen, CEO of Neuralstem.
- Daly receives base salary of $750,000, bonus up to 75% of base, stock options for 1,365,319 shares at $13.30.
- Options and restricted stock units vest in 5 annual installments starting Jan 1, 2025.
- Daly to become consultant from Dec 1, 2023 for transition with McEnany.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312523259961/0001193125-23-259961-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312523259961/d514248d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-259961

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer